Zanubrutinib for Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukaemia: Long-Term Follow-Up of the Phase I/II AU-003 Study

Authors

Akash Mukherjee
Denái R Milton
Elias J Jabbour
Alison M Gulbis
Tapan Kadia
Nitin Jain
Celina Ledesma
Jan Burger
Alessandra Ferrajoli
William Wierda
L Jeffrey Medeiros
Hagop Kantarjian
Richard Champlin
Issa F Khouri

Publication Date

4-1-2022

Journal

Leukemia & Lymphoma

Abstract

We aimed to study the risks of graft-versus-host disease (GVHD), non-relapse mortality (NRM) and survival outcomes of allogeneic stem cell transplantation (alloSCT) in patients with chronic lymphocytic leukemia (n = 17), Richter's syndrome (n = 14), or lymphoma (n = 18) after small molecule inhibitors (SMIs). Patients had a median of 4 prior therapies, including ibrutinib (n = 46; 94%), venetoclax (n = 19; 39%), and idelalisib (n = 6; 12%). Twenty-one (43%) had >1 SMI. P53 mutation was detected in 58% of patients. The 3-year overall and progression-free survival rates were 68% and 59%, respectively. The rates of grade II-IV and III-IV acute GVHD were 33% and 7%. The 1-year rates of chronic GVHD, NRM and relapse were 19%, 10% and 21%, respectively. Results were comparable to a historical control of patients who received alloSCT without a prior exposure to SMI. We conclude that a prior use of SMI does not impair the outcomes after alloSCT.

Keywords

Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Recurrence, Stem Cell Transplantation, Transplantation Conditioning, Treatment Outcome, AllosSCT, small molecule inhibitors, b-cell malignancies

DOI

10.1080/10428194.2022.2043302

PMID

35225133

PMCID

PMC9730341

PubMedCentral® Posted Date

4-1-2023

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes